Aratana Therapeutics Inc (PETX) 16.52 $PETX
Aratana Therapeutics Provides Product Updates
PR Newswire - Tue Feb 10, 4:00PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today provided several product updates. The company continues to advance its deep pipeline of novel therapeutics, including four products at pivotal stage (AT-001, AT-002, AT-003 and AT-014) and two products in post-approval marketing studies (AT-004 and AT-005). Aratana remains on track to achieve additional significant inflection points for its programs in 2015, including results from pivotal field effectiveness studies of AT-002 and AT-003, each in dogs.
PETX: 16.52 (-0.10)
Aratana Therapeutics to Present at the Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 3:00PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will present at the Leerink Global Healthcare Conference to be held February 11-12, 2015, at the Waldorf Astoria Hotel in New York.
PETX: 16.52 (-0.10)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Weakness Seen in Ardelyx (ARDX): Stock Plunges 28.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:37AM CST
Ardelyx saw a big move last session, as the company’s shares fell by nearly 29% on the day.
PETX: 16.52 (-0.10), ARDX: 17.14 (+0.71)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Radius Health (RDUS) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:30AM CST
Radius Health, Inc. (RDUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
RDUS: 50.37 (+0.63), PETX: 16.52 (-0.10)
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2
GlobeNewswire - Thu Jan 22, 10:00AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product for HER2 expressing cancers, is expected to begin patient enrollment in the first half of 2015. In May 2014, Advaxis was granted orphan drug designation by the FDA for ADXS-HER2 in osteosarcoma.
ADXS: 7.18 (+0.06), PETX: 16.52 (-0.10)
Aratana Therapeutics (PETX) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 6:00AM CST
Aratana Therapeutics (PETX) Stock: Moving Average Crossover Alert
PETX: 16.52 (-0.10)
Aratana Therapeutics Awarded "Best Pipeline 2014" by Animal Pharm
PR Newswire - Mon Jan 19, 8:00AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced it has received the "Best Pipeline 2014" award from Animal Pharm, a leading online business intelligence service for the animal health sector. Animal Pharm noted that Aratana was selected for the award based on "the depth of its pipeline and the potentially lucrative opportunity the firm faces."
PETX: 16.52 (-0.10)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 4.07 (+0.04), STZ: 113.03 (-0.48), CRDS: 2.32 (+0.05), PETX: 16.52 (-0.10), NNVC: 2.97 (-0.05), RM: 15.88 (+0.96), ALL: 71.46 (-0.11), TNET: 36.49 (+0.76), SFST: 17.20 (-0.42), AGEN: 5.03 (-0.01), GES: 19.01 (+0.49), WIW: 11.29 (unch), LRCX: 82.21 (+1.10), COST: 147.10 (-0.66), EBF: 13.90 (+0.02), TWTR: 48.50 (+0.55), JGW: 10.70 (-0.16), WIA: 11.49 (-0.03)
Sage Therapeutics (SAGE) in Focus: Stock Falls 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:51AM CST
Sage Therapeutics' shares fell over 7% reversing the uptrend as the stock is now up around 9% since Dec 31
SAGE: 41.03 (-0.07), PETX: 16.52 (-0.10)
Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:44AM CST
Cardiome Pharma Corp. (CRME) was a big mover last session, as the company saw its shares rise a little over 5%
CRME: 9.76 (-0.14), PETX: 16.52 (-0.10)
Can The Uptrend Continue for Aratana (PETX)?
Aratana Therapeutics Provides Product Updates
PR Newswire - Tue Feb 10, 4:00PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today provided several product updates. The company continues to advance its deep pipeline of novel therapeutics, including four products at pivotal stage (AT-001, AT-002, AT-003 and AT-014) and two products in post-approval marketing studies (AT-004 and AT-005). Aratana remains on track to achieve additional significant inflection points for its programs in 2015, including results from pivotal field effectiveness studies of AT-002 and AT-003, each in dogs.
PETX: 16.52 (-0.10)
Aratana Therapeutics to Present at the Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 3:00PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will present at the Leerink Global Healthcare Conference to be held February 11-12, 2015, at the Waldorf Astoria Hotel in New York.
PETX: 16.52 (-0.10)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Weakness Seen in Ardelyx (ARDX): Stock Plunges 28.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:37AM CST
Ardelyx saw a big move last session, as the company’s shares fell by nearly 29% on the day.
PETX: 16.52 (-0.10), ARDX: 17.14 (+0.71)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Radius Health (RDUS) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:30AM CST
Radius Health, Inc. (RDUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
RDUS: 50.37 (+0.63), PETX: 16.52 (-0.10)
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2
GlobeNewswire - Thu Jan 22, 10:00AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product for HER2 expressing cancers, is expected to begin patient enrollment in the first half of 2015. In May 2014, Advaxis was granted orphan drug designation by the FDA for ADXS-HER2 in osteosarcoma.
ADXS: 7.18 (+0.06), PETX: 16.52 (-0.10)
Aratana Therapeutics (PETX) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 6:00AM CST
Aratana Therapeutics (PETX) Stock: Moving Average Crossover Alert
PETX: 16.52 (-0.10)
Aratana Therapeutics Awarded "Best Pipeline 2014" by Animal Pharm
PR Newswire - Mon Jan 19, 8:00AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced it has received the "Best Pipeline 2014" award from Animal Pharm, a leading online business intelligence service for the animal health sector. Animal Pharm noted that Aratana was selected for the award based on "the depth of its pipeline and the potentially lucrative opportunity the firm faces."
PETX: 16.52 (-0.10)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 4.07 (+0.04), STZ: 113.03 (-0.48), CRDS: 2.32 (+0.05), PETX: 16.52 (-0.10), NNVC: 2.97 (-0.05), RM: 15.88 (+0.96), ALL: 71.46 (-0.11), TNET: 36.49 (+0.76), SFST: 17.20 (-0.42), AGEN: 5.03 (-0.01), GES: 19.01 (+0.49), WIW: 11.29 (unch), LRCX: 82.21 (+1.10), COST: 147.10 (-0.66), EBF: 13.90 (+0.02), TWTR: 48.50 (+0.55), JGW: 10.70 (-0.16), WIA: 11.49 (-0.03)
Sage Therapeutics (SAGE) in Focus: Stock Falls 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:51AM CST
Sage Therapeutics' shares fell over 7% reversing the uptrend as the stock is now up around 9% since Dec 31
SAGE: 41.03 (-0.07), PETX: 16.52 (-0.10)
Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:44AM CST
Cardiome Pharma Corp. (CRME) was a big mover last session, as the company saw its shares rise a little over 5%
CRME: 9.76 (-0.14), PETX: 16.52 (-0.10)
Can The Uptrend Continue for Aratana (PETX)?
